AbbVie to invest $380 million to expand US manufacturing in Illinois

robot
摘要生成中

AbbVie plans to invest $380 million to construct two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus. This expansion will boost domestic production capacity for its neuroscience and obesity medicines, aligning with efforts to shore up U.S. manufacturing amid new tariffs on pharmaceutical imports. The new facilities, expected to be operational in 2029, will create 300 jobs and integrate advanced manufacturing technologies and AI.

此页面可能包含第三方内容,仅供参考(非陈述/保证),不应被视为 Gate 认可其观点表述,也不得被视为财务或专业建议。详见声明
  • 赞赏
  • 评论
  • 转发
  • 分享
评论
请输入评论内容
请输入评论内容
暂无评论